Bioventus selects Medservice to distribute Durolane in Russia
Bioventus announced it has selected Medservice to distribute Durolane in Russia.
According to a company press release, Durolane is a single-injection joint fluid based on the highly purified non-animal, stabilized hyaluronic acid (NASHA) process. The NASHA process reportedly yields stabilized hyaluronic acid, which is a naturally occurring molecule that provides lubrication and cushioning in joints.
In Russia, Medservice will offer the standard 3 mL dose of Durolane for the symptomatic treatment of mild to moderate knee or hip osteoarthritis and the 1 mL dose of Durolane, called Durolane SJ, for the treatment of mild to moderate osteoarthritis pain of the ankle, elbow, wrist, fingers and toes.
“We are pleased to make Durolane available to patients in Russia again,” Tony Bihl, chief executive officer of Bioventus, said in the release. “This market is important to our growth in Europe and our international growth strategy overall as we strive to bring our orthobiologic solutions to patients worldwide.”